Daniel J Drucker

A clinician scientist at LTRI @sinaihealth studying GLP-1, diabetes, obesity and the gut endocrine system Proud 🇨🇦Not going anywhere Am 🇮🇱Chai

[Daniel J Drucker @DanielJDrucker]

How do GLP-1 meds improve liver health through #weightloss independent mechanisms? Here @ChusaGzlzRellan & colleagues identify Liver Sinusoidal Endothelial Cells as direct targets of semaglutide, linking LSECs to reduction of #inflammation #Fibrosis #MASH https://t.co/c5FXIs2hTO

[Daniel J Drucker @DanielJDrucker]

Automated CT-derived Perivascular Adipose Tissue biomarkers are associated with existing and future #T2D and may enable identification of undiagnosed or high-risk individuals undergoing routine abdominal CT https://t.co/LO8Hke69MQ

[Daniel J Drucker @DanielJDrucker]

Rates of anxiety and depression in real world data from Shanghai in people with #T2D using GLP-1 medicines are low but increase slightly after discontinuation of the medicines @NatMetabolism https://t.co/sHXX5TN5R6

[Daniel J Drucker @DanielJDrucker]

Evaluating the progress in biological clocks #Aging @EricTopol @NatureMedicine https://t.co/nHmW81a9AZ

[Daniel J Drucker @DanielJDrucker]

P3 data assessing the efficacy and safety of setmelanotide once daily in acquired hypothalamic obesity over 52 weeks https://t.co/uCmhEsSeNJ

[Daniel J Drucker @DanielJDrucker]

More evidence from studies of mice deficient in α cells that α cells are required for nutrient homeostasis by regulating the dynamics of β cell networks, notably under conditions of amino acid exposure https://t.co/y1MfIDdzgi

[Daniel J Drucker @DanielJDrucker]

Assessment of body composition remodeling during the trajectory of #T2D https://t.co/yxd2yngWPy

[Daniel J Drucker @DanielJDrucker]

It seems increasingly likely that information derived from proteomic clocks will be useful for enrolling clinical trials and for risk stratification in the clinic https://t.co/2yUjsdIMqu

[Daniel J Drucker @DanielJDrucker]

New studies in mice and human islets interrogate direct islet vs. Tanycyte dependent actions of liraglutide to control insulin secretion and glucose homeostasis, emphasizing the importance of the glycemic state for liraglutide action https://t.co/hjK8uzyUpO @DiabetologiaJnl

[Daniel J Drucker @DanielJDrucker]

The rapid rise of TriNetX-so many papers, hundreds of new associations-cause for celebration, concern, or simply careful scrutiny? @ScienceMagazine https://t.co/eDx6PaB1v9

[Daniel J Drucker @DanielJDrucker]

α-cell-derived glucagon positioned as a gatekeeper of immune and neuronal control of insulin secretion at fasting glucose in mice @CellReports https://t.co/1sBKrZEbEf

[Daniel J Drucker @DanielJDrucker]

A reminder of the benefits of exercise for cardiovascular health. In adults with #obesity, regular physical activity over 52 wks, with or without GLP-1R agonists, but not liraglutide alone, promotes vascular health & ⬇️CMT over in adults with obesity. https://t.co/366vC4XeMv

[Daniel J Drucker @DanielJDrucker]

In a mouse model of obesity-induced metabolic inflammation that accelerates leukemogenesis, dual therapy with an anti-IL-17A antibody and a GLP-1R agonist reduced leukemic burden, findings supported by clinical phenotyping @uk_biobank https://t.co/7uT8bQEKZU

[Daniel J Drucker @DanielJDrucker]

A metabolic update and perspective on #MASLD #MASH @DiabetologiaJnl https://t.co/IJGS7urfBI

[Daniel J Drucker @DanielJDrucker]

Adiposity and #cancer Will use of GLP-1 medicines bend the curve? Is weight loss the potential mechanistic driver? https://t.co/y8gGtPgdyq

[Daniel J Drucker @DanielJDrucker]

Here the authors present evidence in mice that liraglutide promotes anti-depressant actions independent of the GLP-1R by modulating a microbiota-endocannabinoid metabolic pathway, revealing a potential therapeutic target for depression @cellhostmicrobe https://t.co/MKoS5VDXts

[Daniel J Drucker @DanielJDrucker]

The next chapter from Prof Steven Kahn clearly conceived before #ADA2026 now more timely, published in @DiabetesCareADA https://t.co/2UanIUjXQe #Diabetes

[Daniel J Drucker @DanielJDrucker]

Understanding the determinants of and ways to mitigate #exercise associated nocturnal #hypoglycemia in adults with type 1 #diabetes https://t.co/dgpRpu8RtG #ADA2026

[Daniel J Drucker @DanielJDrucker]

Registry data from Hong Kong demonstrates that hyperglycaemic exposure was associated with an elevated long-term cancer risk in type 2 diabetes and earlier high HbA1c exposures contributed more strongly to cancer risk than later exposures @DiabetologiaJnl https://t.co/mPDIrstxyn

[Eric Topol @EricTopol]

@DanielJDrucker @NatureCancer More than 40 studies @ASCO consistent on this topic for link between GLP-1 drugs and reduced cancer incidence or improved prognosis
https://t.co/Q0asxhH4IV @arianaeunjung @PostRowland

[Daniel J Drucker @DanielJDrucker]

New from Professor Blau, inhibition of the gerozyme 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss https://t.co/yfaYwoOCOr